Subtype
Glioblastoma
CI-CAN-00000934GBMExplore in graph →
486 active trials2 approved drugs43 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000934GBMExplore in graph →
Clinical trials
1,750 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (282)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06616727 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM | enrolling by invitation | Phase 1 | 50 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT06595186 | JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM) | recruiting | Phase 2 | 25 | JenKem Technology Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04933422 | CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM) | not yet recruiting | Phase 1 | 72 | Crimson Biopharm Inc.INDUSTRY | 0 | Aug 21, 2024 | clinicaltrials |
| NCT06524063 | Targeted Survivin DC Cell Injection for the Treatment of GBM | not yet recruiting | Phase 1 | 9 | Beijing Tricision Biotherapeutics IncINDUSTRY | 0 | Jul 29, 2024 | clinicaltrials |
| NCT05990556 | Research on the Safety and Efficacy of Blocking Dural Blood Supply in Glioblastoma Patients | recruiting | N/A | 20 | First Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06480721 | FET-PET-Guided Management of Pseudoprogression in Glioblastoma(FET-POPPING) | not yet recruiting | N/A | 144 | Veerle RuijtersOTHER | 1 | Jun 28, 2024 | clinicaltrials |
| NCT06477939 | Study of Adding or Not Liposomal Transcrocetin (L-TC) With Concomitant HypoFractionated Radiation ThErapy and TEmozolomide in Newly Diagnosed GLioblastoma (GBM) Patients(THREE-GLEES) | not yet recruiting | Phase 3 | 554 | Institut de cancérologie Strasbourg EuropeOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT06418113 | Neoadjuvant Radio-chemotherapy Safety Pilot Study in Patients With Glioblastoma(GLINERA) | recruiting | Phase 1 | 12 | Hospital San Carlos, MadridOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT05664464 | Glutamate Inhibitors in Glioblastoma(GLUGLIO) | recruiting | Phase 1 / Phase 2 | 120 | University of ZurichOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT05768087 | Escalated Dose Proton Therapy Within the Multimodality Treatment of Glioblastoma Patients | recruiting | N/A | 36 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT03899857 | Pembrolizumab for Newly Diagnosed Glioblastoma(PERGOLA) | active not recruiting | Phase 2 | 56 | University of ZurichOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06396481 | Clinical Study of Allogeneic Vγ9Vδ2 T Cells in the Treatment of Brain Malignant Glioma(CSAγδTBMG) | not yet recruiting | Early Phase 1 | 25 | Beijing Tiantan HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT06368934 | Sub-lobectomy for IDH Wild-type and TERT Promoter Mutant Glioblastoma | not yet recruiting | N/A | 326 | Huashan HospitalOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT05577091 | Tris-CAR-T Cell Therapy for Recurrent Glioblastoma | recruiting | Phase 1 | 10 | Beijing Tiantan HospitalOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05318612 | Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)(EMITT) | active not recruiting | Phase 3 | 238 | Radboud University Medical CenterOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06327451 | Evaluate the Efficacy and Safety of Atorvastatin Combined With Temozolomide in the Treatment of Glioblastoma | recruiting | Phase 2 | 50 | Tianjin Medical University General HospitalOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06297512 | Evaluate the Role of Anthracycline After Radio Therapy in Patients With Glioblastoma (pGBM). | recruiting | Phase 2 | 20 | Iacopo SardiOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT06283927 | The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)(RECSUR) | recruiting | — | 464 | Jasper GerritsenOTHER | 5 | Feb 28, 2024 | clinicaltrials |
| NCT06271421 | NanoTherm In Adjuvant Therapy of Glioblastoma Multiforme(ANCHIALE) | recruiting | N/A | 100 | Poznan University of Medical SciencesOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06118723 | The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)(SUPRAMAX) | recruiting | — | 784 | Jasper GerritsenOTHER | 5 | Feb 22, 2024 | clinicaltrials |
| NCT06273176 | The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma(RECMAP) | recruiting | — | 225 | Erasmus Medical CenterOTHER | 5 | Feb 22, 2024 | clinicaltrials |
| NCT06041555 | MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)(ISRAR) | recruiting | — | 600 | Hospices Civils de LyonOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06001281 | Predictive Value of Soluble CD146 in Glioblastoma Patients(MUCIGLIO-01) | recruiting | N/A | 55 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT06220552 | The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma | recruiting | Phase 2 | 20 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT06218524 | The Effectiveness of HP and TMZ Synergism on Adult Recurrence GBM | not yet recruiting | Phase 2 | 200 | Southern Medical University, ChinaOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05908669 | Deuterium Metabolic Imaging to Assess Radiotherapy Changes in Glioblastoma Multiforme | enrolling by invitation | — | 10 | University of AarhusOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06160596 | Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis(ROSALIND) | recruiting | — | 1,020 | Cure 51OTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT06146725 | The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)(RESBIOP) | recruiting | — | 564 | Jasper GerritsenOTHER | 5 | Nov 27, 2023 | clinicaltrials |
| NCT06146738 | The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)(PALSUR) | recruiting | — | 1,015 | Jasper GerritsenOTHER | 5 | Nov 27, 2023 | clinicaltrials |
| NCT03861299 | The SAFE-Trial: Awake Craniotomy Versus Surgery Under General Anesthesia for Glioblastoma Patients.(SAFE) | recruiting | N/A | 246 | Jasper GerritsenOTHER | 2 | Nov 21, 2023 | clinicaltrials |
| NCT04443010 | Safety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma(GLIOSUN) | recruiting | Phase 1 / Phase 2 | 226 | Philogen S.p.A.INDUSTRY | 1 | Oct 10, 2023 | clinicaltrials |
| NCT05540275 | Tislelizumab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for Bevacizumab Refractory Recurrent Glioblastoma | not yet recruiting | Phase 2 | 30 | Henan Provincial People's HospitalOTHER | 1 | Oct 6, 2023 | clinicaltrials |
| NCT06017063 | Coaching for Coping in Glioblastoma Patients and Caregivers and Its Association With Compliance to TTFields(COCOON) | not yet recruiting | N/A | 275 | University Hospital TuebingenOTHER | 0 | Aug 30, 2023 | clinicaltrials |
| NCT05917821 | New Antigens Against Glioblastoma(INAAG) | not yet recruiting | — | 120 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 0 | Jul 24, 2023 | clinicaltrials |
| NCT05842746 | Elemene Plus Stupp Protocol Versus Stupp Protocol Alone for Newly-diagnosed Glioblastoma | not yet recruiting | Phase 2 | 74 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05326334 | THERApeutic Outcomes Related to Gut microBIOME in Glioblastoma (GBM) Patients Receiving Chemo-radiation (THERABIOME-GBM)(THERABIOME-GBM) | recruiting | — | 20 | Ottawa Hospital Research InstituteOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05100641 | AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM | not yet recruiting | Phase 3 | 672 | Aivita Biomedical, Inc.INDUSTRY | 0 | Apr 10, 2023 | clinicaltrials |
| NCT05641220 | Biopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study.(BIOPSY) | not yet recruiting | — | 325 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05502991 | Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma | not yet recruiting | Phase 2 | 60 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT05541042 | Radiogenomics in Glioblastoma: Correlation Between Multiparametric Imaging Biomarkers and Genetic Biomarkers | not yet recruiting | — | 50 | Henan Provincial People's HospitalOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT04708171 | The PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections(PROGRAM) | recruiting | — | 453 | Erasmus Medical CenterOTHER | 5 | May 6, 2022 | clinicaltrials |
| NCT03787056 | Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients(ONCOPRO) | recruiting | N/A | 410 | Hospices Civils de LyonOTHER | 1 | Jul 16, 2021 | clinicaltrials |
| NCT03005132 | Integrative Analysis of Human Glioblastoma Multiforme | recruiting | — | 1,000 | Shanghai 10th People's HospitalOTHER | 1 | Dec 29, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 27, 2024source: clinicaltrials